Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma 1

Interventions

Cyclophosphamide 41 fludarabine 31 Dexamethasone 27 venetoclax 25 Cytarabine 22 Rituximab 16 pembrolizumab 15 fludarabine phosphate 14 Filgrastim 12 Etoposide 12 Lenalidomide 11 Vincristine 10 Gemcitabine 10 Azacitidine 10 pomalidomide 9 Interleukin-2 9 Granulocyte Colony-Stimulating Factor 9 Doxorubicin 9 Calcium Dobesilate 9 carfilzomib 8 Topotecan 8 Nivolumab 8 Methotrexate 8 Everolimus 8 Decitabine 8 Bortezomib 8 Melphalan 7 Cisplatin 7 Vorinostat 6 Injections 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × TQ-B3525 × Clear all

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡